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Possible Subclinical Leaflet Thrombosis in Bioprosthetic  
Aortic Valves
To the Editor: Makkar et al. describe the phe-
nomenon of reduced leaflet motion in patients 
who had received bioprosthetic aortic valves. An 
in vitro study by Ducci et al.1 showed that TAVR 
produced substantial alteration of the flow pat-
tern in the sinuses of Valsalva, creating regions 
of blood stasis that could lead to thrombus for-
mation. This abnormal condition is not observed 
after conventional surgical aortic-valve replace-
ment because the complete resection of the calci-
fied leaflets allows preservation of the natural 
geometry and vortex dynamics of the aortic root. 
Moreover, with the use of TAVR implants, there 
is often angular or rotational misalignment with 
the sinuses and coronary ostia; this could further 
impair local blood flow.
The data reported by Makkar et al. and Ducci 
et al. suggest that the use of bioprosthetic valves 
per se is not sufficient to guarantee correct leaf-
let dynamics and avoid the need for anticoagula-
tion. This finding may be particularly alarming 
in light of what has been clinically observed 
with surgical bioprostheses.2-4 The data reported 
by Ducci and colleagues need to be taken into 
account when considering the use of TAVR in 
patients who cannot be treated with anticoagu-
lants and in lower-risk patients.
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